Advertisement

Historical Aspects and Frontiers of Parkinson’s Disease Research

  • Oleh Hornykiewicz
Part of the Advances in Experimental Medicine and Biology book series (AEMB)

Abstract

From the historical point of view it would appear that right from the beginning of the era that we call modern medicine, drugs have been regarded as important tools in elucidating the biochemi cal pathology of disease. In the history of Parkinson’s disease there has been hardly a drug that has not been tried as a potential remedy. The long list includes such oddities as ferrisulfate, barium chloride, strychnine, metrazol, thyroid and parathyroid hormones, and — surprizingly — striaphorin, an extract of the striatum. Of all the older antiparkinson drugs, anticholinergics attained special significance because of their unquestionable (though low) therapeutic efficacy. However, these drugs also led the thinking of researchers astray because for a long time the effectiveness of the anticholinergic agents was taken as evidence that Parkinson’s disease may be primarily a disorder of cholinergic brain mechanisms.

Keywords

Basal Ganglion Substantia Nigra Nucleus Accumbens Caudate Nucleus Dopamine Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N.-E. (1974). Inhibition of the turnover of the brain dopamine after treatment with the gamma-aminobutyrate:2-oxyglutarate transaminase inhibitor aminooxyacetic acid. Arch Pharmacol. 283 ,419–424.CrossRefGoogle Scholar
  2. Barbeau, A., Sourkes, T.L. and Murphy, G. (1962). Les catecholamines dans la maladie de Parkinson. In Monoamines et System Nerveux Central (Ajuriaguerra, J.de, Ed.) pp. 247–262. Georg, Geneva and Masson, Paris.Google Scholar
  3. Barolin, G.S., Bernheimer, H. and Hornykiewicz, O. (1964). Seiten verschiedenes Verhalten des Dopamins (3-Hydroxytyramin) im Gehirn eines Falles von Hemiparkinsonismus. Schweiz. Arch. Neurol. Psychûzt. 94 ,241–248.Google Scholar
  4. Bartholini, G., Stadler, H. and Lloyd, K.G. (1975). Cholinergic dopaminergic interregulations within the extrapyramidal sys tem. In Cholinergic Mechanisms (Waser, P.G., Ed.) pp. 411–418. Raven Press, New York.Google Scholar
  5. Bernheimer, H. and Hornykiewicz, O. (1962). Das Verhalten einiger Enzyme im Gehirn normaler und Parkinsonkranker Menschen. Arch. exp. Path. Pharmak. 243 ,295.CrossRefGoogle Scholar
  6. Bernheimer, H. and Hornykiewicz, O. (1965). Herabgesetzte Konzentration der homovanillinsäure im Gehirn von Parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminstoff wechsels. Klin.Wschr. 43 ,711–715.PubMedCrossRefGoogle Scholar
  7. Bernheimer, H., Birkmayer, W. and Hornykiewicz, O. (1961). Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin. Wschr. 39 ,1056–1059.PubMedCrossRefGoogle Scholar
  8. Bernheimer, H., Birkmayer, W. and Hornykiewicz, O. (1963). Zur Biochemie des Parkinson-Syndroms des Menschen. Klin. Wschr. 41 ,465–469.CrossRefGoogle Scholar
  9. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. and Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. J. Neurol. Sci. 20 ,415–455.PubMedCrossRefGoogle Scholar
  10. Bertler, A. and Rosengren, E. (1959). Occurrence and distribution of dopamine in brain and other tissues. Experientia 15 ,10–11.PubMedCrossRefGoogle Scholar
  11. Birkmayer, W. and Hornykiewicz, O. (1961). Der L-Dioxyphenylalanin (= L-D0PA)-Effekt bei der Parkinson-Akinese. Wien.Klin. Wschr. 73 ,787–788.PubMedGoogle Scholar
  12. Carlsson, A. (1959). The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11 ,490–493.PubMedGoogle Scholar
  13. Carlsson, A., Lindqvist, M. and Magnusson, T. (1957). 3,4-Dihydroxy phenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 ,1200.PubMedCrossRefGoogle Scholar
  14. Carlsson, A., Lindqvist, M., Magnusson, T. and Waldeck, B. (1958). On the presence of 3-hydroxytyramine in brain. Science 127 ,471.PubMedCrossRefGoogle Scholar
  15. Cotzias, G.C., Van Woert, M.H. and Schiffer, L.M. (1967). Aromatic amino acids and modification of parkinsonism. New Engl. J. Meä. 276 ,374–379.CrossRefGoogle Scholar
  16. Ehringer, H. and Hornykiewicz, O. (1960). Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin.Wschr. 38 ,1236–1239.PubMedCrossRefGoogle Scholar
  17. Farley, I.J. and Hornykiewicz, O. (1977). Noradrenaline in subcortical brain regions of patients with Parkinson’s disease and control subjects. In Advances in Parkinsonism, Biochem istry, Physiology, Treatment (Birkmayer, W. and Hornykiewicz, O., Eds.) Editiones Roche, Basel (in press).Google Scholar
  18. Farley, I.J., Price, K.S. and Hornykiewicz, O. (1977). Dopamine in the limbic regions of the human brain: normal and abnormal. In Advances in Biochem. Psychopharmacol. vol. 16 (Costa, E. and Gessa, G.L., Eds.) pp. 57–64. Raven Press, New York.Google Scholar
  19. Fuxe, K., Hökfelt, T. and Ungerstedt, U. (1970). Morphological and functional aspects of central monoamine neurons. Int. Rev. Neurobiol. 13 ,93–126.CrossRefGoogle Scholar
  20. Grabowska, M. and Michaluk, J. (1974). On the role of serotonin in apomorphine-induced locomotor stimulation in rats. Pharmacology, Biochemistry and Behavior 2 ,263–266.CrossRefGoogle Scholar
  21. Hollister, A.S., Breese, G.R., Kuhn, C.M., Cooper, B.R. and Shanberg, S.M. (1975). Evidence for an inhibitory function of brain serotonin systems in the locomotor stimulant effects of D-amphetamine. Neurosci. Abstr. 1 ,297.Google Scholar
  22. Hornykiewicz, O. (1963). Die topische Lokalisation und Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Sub stantia nigra des normalen und Parkinsonkranken Menschen. Wien. Klin, W schr. 75 ,309–312.Google Scholar
  23. Hornykiewicz, O. (1976). Neurohumoral interactions and basal ganglia function and dysfunction. In The Basal Ganglia (Yahr, M.D., Ed.) pp. 269–278. Raven Press, New York.Google Scholar
  24. Lahti, R.A. and Losey, E.G. (1974). Antagonism of the effects of chlorpromazine and morphine on dopamine metabolism by GABA. Res. Commun. Chem. Pathol. Pharmacol. 7 ,31–40.PubMedGoogle Scholar
  25. Lloyd, K.G. and Hornykiewicz, O. (1970). Parkinson’s disease: activity of L-DOPA decarboxylase in discrete brain regions. Science 170 ,1212–1213.PubMedCrossRefGoogle Scholar
  26. Lloyd, K.G. and Hornykiewicz, O. (1973). L-Glutamic acid decarboxylase in Parkinson’s disease: effect of L-dopa therapy. Nature 243 ,521–523.PubMedCrossRefGoogle Scholar
  27. Lloyd, K.G. and Hornykiewicz, O. (1975). Catecholamines in regulation of motor function. In Catecholamines and Behavior, vol. 1 (Friedhoff, A.J., Ed.) pp. 41–57. Plenum Publ. Comp., New York.CrossRefGoogle Scholar
  28. Lloyd, K.G., Davidson, L. and Hornykiewicz, O. (1975). The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J. Pharmacol. 195 ,453–464.Google Scholar
  29. Maj, J., Pawlowski, L. and Sarnek, J. (1974). The role of brain 5-hydroxytryptamine in the central action of L-DOPA. In Advances in Biochem. Psychopharmacol. vol. 10 (Costa, E., Gessa, G.L. and Sandier, M., Eds.) pp. 253–256. Raven Press, New York.Google Scholar
  30. Nauta, W.J.H. (1977). Some cross-roads of limbic and striatal circuitry. In The Continuing Evolution of the Limbic System Concept (Livingston, K. and Hornykiewicz, O., Eds.). Plenum Press, New York (in press).Google Scholar
  31. Pijnenburg. A.J.J., Honig, W.M.M., Van der Heyden, J.A.M. and Van Rossum, J.M. (1976). Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Europ. J. Pharmacol. 35 ,45–58.CrossRefGoogle Scholar
  32. Raab, W. and Gigee, W. (1951). Concentration and distribution of “encephalin” in the brain of humans and animals. Proa. Soc. exp. Bio. 76 ,97–100.Google Scholar
  33. Tarsy, D., Pycock, C., Meldrum, B. and Marsden, C.D. (1975). Rotational behaviour induced in rats by intranigral picrotoxin. Brain Res. 89 ,160–165.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Oleh Hornykiewicz
    • 1
  1. 1.Institute of Biochemical PharmacologyUniversity of ViennaViennaAustria

Personalised recommendations